Amgen's Dazodalibep Shows Promise in Systemic Sjögren's Disease Trial

Amgen Inc. (NASDAQ:AMGN) recently announced positive Phase 3 trial results for its dazodalibep treatment in systemic Sjögren's disease.

The trial met its primary endpoint, demonstrating statistically significant and clinically meaningful improvements in systemic disease activity.

Citi reaffirmed a Neutral rating and $405 price target on Amgen after the announcement, noting that while the results reduce clinical risk for dazodalibep, critical details were omitted from the release.

The true commercial potential of dazodalibep remains an open question until comprehensive data are disclosed, according to Citi.